<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00490035</url>
  </required_header>
  <id_info>
    <org_study_id>N01252</org_study_id>
    <secondary_id>2006-006344-59</secondary_id>
    <nct_id>NCT00490035</nct_id>
  </id_info>
  <brief_title>Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures</brief_title>
  <official_title>A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (&gt;= 16 to 70 Years Old) With Partial Onset Seizures.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UCB Pharma SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UCB Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the efficacy and safety of Brivaracetam to support the submission
      file in the indication of adjunctive treatment in adolescents and adults with partial onset
      seizures.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2007</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>Partial (Type I) Seizures can be classified into one of the following three groups: Simple Partial Seizures, Complex Partial Seizures, Partial Seizures evolving to Secondarily Generalized Seizures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Responder Rate for Partial Onset Seizures (Type I) Frequency Per Week Over the 12-week Treatment Period</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>Responders are those subjects with at least 50 % reduction from Baseline to Treatment Period in Partial Onset Seizure frequency per week.
The Responder Rate for Partial Onset Seizures (Type I) is the proportion of subjects who have a &gt;= 50 % reduction in seizure frequency per week from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All Seizure Frequency (Type I+II+III) Per Week Over the 12-week Treatment Period</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>There are three types of Epilepsy: Partial Epilepsies (Type I), Generalized Epilepsies (Type II) and uncertain classification of Epilepsies (Type III).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent Change From Baseline to the 12-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>The percent change from Baseline was computed as: Weekly Seizure Frequency (Treatment) - Weekly Seizure Frequency (Baseline) / Weekly Seizure Frequency (Baseline) * 100. Negative values indicate a reduction from Baseline with higher negative values showing higher reduction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Categorized Percentage Change From Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the 12-week Treatment Period</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>The categories are:
&lt;= 25 %
- 25 % to &lt; 25 %
25 % to &lt; 50 %
50 % to &lt; 75 %
75 % to &lt; 100 %
100 %</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Seizure Freedom Rate (All Seizure Types) Over the 12-week Treatment Period</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>Subjects were considered seizure free if their seizure counts for every day over the entire Treatment Period was zero and if they completed the Treatment Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Type I Seizure During the 12-week Treatment Period</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>The time to first Type I Seizure during the 12-week Treatment Period was measured in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Fifth Type I Seizure During the 12-week Treatment Period</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>The time to Fifth Type I Seizure during the 12-week Treatment Period was measured in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Tenth Type I Seizure During the 12-week Treatment Period</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>The time to tenth Type I Seizure during the 12-week Treatment Period was measured in days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 12- Week Treatment Period.</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the 12-week Treatment Period in Daily Activities/Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the 12-week Treatment Period in Hospital Anxiety Score</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the 12-week Treatment Period in Hospital Depression Score</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit</measure>
    <time_frame>Last Visit or Early Discontinuation Visit in the 12-week Treatment Period</time_frame>
    <description>The Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The subject not mentally impaired had to complete it by answering the following question: &quot;Overall, has there been a change in your seizures since the start of the study medication?&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit</measure>
    <time_frame>Last Visit or Early Discontinuation Visit in the 12-week Treatment Period</time_frame>
    <description>The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement), with the start of the study medication as reference time point. The Investigator was to complete it by answering the following question: &quot;Assess the Overall change in the severity of patient's illness, compared to start of study medication.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the 12-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the 12-week Treatment Period in Emotional Well-Being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the 12-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the 12-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the 12-week Treatment Period in Overall Quality of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to the 12-week Treatment Period in Health Status of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</measure>
    <time_frame>From Baseline to 12-week Treatment Period</time_frame>
    <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">399</enrollment>
  <condition>Epilepsy</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching Placebo tablets administered twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brivaracetam 20 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brivaracetam 50 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Brivaracetam 100 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brivaracetam</intervention_name>
    <description>Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period</description>
    <arm_group_label>Brivaracetam 20 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brivaracetam</intervention_name>
    <description>Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day in a double-blinded way for the 12-week Treatment Period.</description>
    <arm_group_label>Brivaracetam 50 mg/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Brivaracetam</intervention_name>
    <description>Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 100 mg /day in a double-blinded way for the 12-week Treatment Period.</description>
    <arm_group_label>Brivaracetam 100 mg/day</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects were from 16 to 70 years, both inclusive. Subjects under 18 years of age were
             only included where legally permitted and ethically accepted

          -  Subjects with well-characterized focal epilepsy or epileptic syndrome according to the
             International League Against Epilepsy (ILAE) classification

          -  Subjects had a history of partial onset seizures (POS) whether or not secondarily
             generalized (Type I seizures according to the ILAE classification)

          -  Subjects had at least 2 POS whether or not secondarily generalized per month during
             the 3 months preceding Visit 1

          -  Subjects had at least 8 POS whether or not secondarily generalized during the 8-Week
             Baseline Period

          -  Subjects were uncontrolled while treated by 1 to 2 permitted concomitant antiepileptic
             drugs (AEDs). Vagal nerve stimulation was allowed and was not counted as a concomitant
             AED

        Exclusion Criteria:

          -  History or presence of seizures occurring only in clusters (too frequently or
             indistinctly separated to be reliably counted) before Visit 3

          -  History or presence of status epilepticus during the year preceding Visit 1 or during
             Baseline
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>UCB Clinical Trial Call Center</last_name>
    <role>Study Director</role>
    <affiliation>+1 877 822 9493 (UCB)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>13</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>19</name>
      <address>
        <city>La Louviere</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>12</name>
      <address>
        <city>Liege</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>10</name>
      <address>
        <city>Saint-Vith</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>44</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>41</name>
      <address>
        <city>Oulu</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>42</name>
      <address>
        <city>Seinajoki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>43</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>60</name>
      <address>
        <city>Angers Cedex 9</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>56</name>
      <address>
        <city>Bethune</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>62</name>
      <address>
        <city>Bron</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>57</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>53</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>52</name>
      <address>
        <city>Montpellier Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>64</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>54</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>51</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>61</name>
      <address>
        <city>Roanne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>55</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>76</name>
      <address>
        <city>Bad Berka</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>73</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>79</name>
      <address>
        <city>Bernau</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>78</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>74</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>75</name>
      <address>
        <city>Kehl-Kork</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>77</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>70</name>
      <address>
        <city>Munchen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>72</name>
      <address>
        <city>Radeberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>71</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>94</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>90</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>92</name>
      <address>
        <city>Pecs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>256</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>257</name>
      <address>
        <city>Bangalore</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>253</name>
      <address>
        <city>Hyderabad</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>258</name>
      <address>
        <city>Jaipur</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>255</name>
      <address>
        <city>Kolkata</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>250</name>
      <address>
        <city>Lucknow</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>259</name>
      <address>
        <city>Mumbai</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>251</name>
      <address>
        <city>Pune Maharashtra</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>270</name>
      <address>
        <city>Pune</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>104</name>
      <address>
        <city>Bologna</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>105</name>
      <address>
        <city>Foggia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>101</name>
      <address>
        <city>Perugia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>103</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>107</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>124</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>125</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>122</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>142</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>143</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>153</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>147</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>151</name>
      <address>
        <city>Katowice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>141</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>150</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>148</name>
      <address>
        <city>Lodz</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>144</name>
      <address>
        <city>Lublin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>152</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>146</name>
      <address>
        <city>Szczecin</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>145</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>140</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>149</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>187</name>
      <address>
        <city>Alcorcon</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>181</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>182</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>184</name>
      <address>
        <city>San Sebastian</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>183</name>
      <address>
        <city>Vigo</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>185</name>
      <address>
        <city>Zaragoza</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>201</name>
      <address>
        <city>Biel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>205</name>
      <address>
        <city>Geneve</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>203</name>
      <address>
        <city>St Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>202</name>
      <address>
        <city>Tschugg</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>204</name>
      <address>
        <city>Zürich</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>223</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>224</name>
      <address>
        <city>Middlesborough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Switzerland</country>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Ryvlin P, Werhahn KJ, Blaszczyk B, Johnson ME, Lu S. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a double-blind, randomized, placebo-controlled trial. Epilepsia. 2014 Jan;55(1):47-56. doi: 10.1111/epi.12432. Epub 2013 Oct 28.</citation>
    <PMID>24256083</PMID>
  </results_reference>
  <results_reference>
    <citation>Toledo M, Whitesides J, Schiemann J, Johnson ME, Eckhardt K, McDonough B, Borghs S, Kwan P. Safety, tolerability, and seizure control during long-term treatment with adjunctive brivaracetam for partial-onset seizures. Epilepsia. 2016 Jul;57(7):1139-51. doi: 10.1111/epi.13416. Epub 2016 Jun 6.</citation>
    <PMID>27265725</PMID>
  </results_reference>
  <results_reference>
    <citation>Ben-Menachem E, Mameniškienė R, Quarato PP, Klein P, Gamage J, Schiemann J, Johnson ME, Whitesides J, McDonough B, Eckhardt K. Efficacy and safety of brivaracetam for partial-onset seizures in 3 pooled clinical studies. Neurology. 2016 Jul 19;87(3):314-23. doi: 10.1212/WNL.0000000000002864. Epub 2016 Jun 22.</citation>
    <PMID>27335114</PMID>
  </results_reference>
  <results_reference>
    <citation>Brodie MJ, Whitesides J, Schiemann J, D'Souza J, Johnson ME. Tolerability, safety, and efficacy of adjunctive brivaracetam for focal seizures in older patients: A pooled analysis from three phase III studies. Epilepsy Res. 2016 Nov;127:114-118. doi: 10.1016/j.eplepsyres.2016.08.018. Epub 2016 Aug 18.</citation>
    <PMID>27589414</PMID>
  </results_reference>
  <results_reference>
    <citation>Mukuria C, Young T, Keetharuth A, Borghs S, Brazier J. Sensitivity and responsiveness of the EQ-5D-3L in patients with uncontrolled focal seizures: an analysis of Phase III trials of adjunctive brivaracetam. Qual Life Res. 2017 Mar;26(3):749-759. doi: 10.1007/s11136-016-1483-3. Epub 2016 Dec 21.</citation>
    <PMID>28004320</PMID>
  </results_reference>
  <results_reference>
    <citation>Moseley BD, Sperling MR, Asadi-Pooya AA, Diaz A, Elmouft S, Schiemann J, Whitesides J. Efficacy, safety, and tolerability of adjunctive brivaracetam for secondarily generalized tonic-clonic seizures: Pooled results from three Phase III studies. Epilepsy Res. 2016 Nov;127:179-185. doi: 10.1016/j.eplepsyres.2016.09.003. Epub 2016 Sep 3.</citation>
    <PMID>27608437</PMID>
  </results_reference>
  <results_reference>
    <citation>Brandt C, Borghs S, Elmoufti S, Mueller K, Townsend R, de la Loge C. Health-related quality of life in double-blind Phase III studies of brivaracetam as adjunctive therapy of focal seizures: A pooled, post-hoc analysis. Epilepsy Behav. 2017 Apr;69:80-85. doi: 10.1016/j.yebeh.2016.11.031. Epub 2017 Feb 23.</citation>
    <PMID>28236727</PMID>
  </results_reference>
  <results_reference>
    <citation>Klein P, Johnson ME, Schiemann J, Whitesides J. Time to onset of sustained ≥50% responder status in patients with focal (partial-onset) seizures in three phase III studies of adjunctive brivaracetam treatment. Epilepsia. 2017 Feb;58(2):e21-e25. doi: 10.1111/epi.13631. Epub 2016 Dec 18.</citation>
    <PMID>27988967</PMID>
  </results_reference>
  <results_reference>
    <citation>Asadi-Pooya AA, Sperling MR, Chung S, Klein P, Diaz A, Elmoufti S, Schiemann J, Whitesides J. Efficacy and tolerability of adjunctive brivaracetam in patients with prior antiepileptic drug exposure: A post-hoc study. Epilepsy Res. 2017 Mar;131:70-75. doi: 10.1016/j.eplepsyres.2017.02.007. Epub 2017 Feb 27.</citation>
    <PMID>28279891</PMID>
  </results_reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 21, 2007</study_first_submitted>
  <study_first_submitted_qc>June 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2007</study_first_posted>
  <results_first_submitted>March 14, 2016</results_first_submitted>
  <results_first_submitted_qc>March 14, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 13, 2016</results_first_posted>
  <disposition_first_submitted>February 24, 2010</disposition_first_submitted>
  <disposition_first_submitted_qc>August 26, 2009</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">August 27, 2009</disposition_first_posted>
  <last_update_submitted>December 11, 2017</last_update_submitted>
  <last_update_submitted_qc>December 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">January 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epilepsy</keyword>
  <keyword>Brivaracetam</keyword>
  <keyword>Partial Onset Seizures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Seizures</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Brivaracetam</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study started to enroll subjects in September 2007 and concluded in February 2009.</recruitment_details>
      <pre_assignment_details>Participant Flow refers to the Randomized Set.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Matching Placebo tablets administered twice a day</description>
        </group>
        <group group_id="P2">
          <title>Brivaracetam 20 mg/Day</title>
          <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
        </group>
        <group group_id="P3">
          <title>Brivaracetam 50 mg/Day</title>
          <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
        </group>
        <group group_id="P4">
          <title>Brivaracetam 100 mg/Day</title>
          <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="99"/>
                <participants group_id="P3" count="100"/>
                <participants group_id="P4" count="100"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="92"/>
                <participants group_id="P2" count="93"/>
                <participants group_id="P3" count="88"/>
                <participants group_id="P4" count="94"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>AE, non-serious non-fatal</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other reason</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE, serious fatal</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious adverse event (SAE), non-fatal</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>AE of unknown type</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Baseline Characteristics refer to the Randomized Set.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Matching Placebo tablets administered twice a day</description>
        </group>
        <group group_id="B2">
          <title>Brivaracetam 20 mg/Day</title>
          <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
        </group>
        <group group_id="B3">
          <title>Brivaracetam 50 mg/Day</title>
          <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
        </group>
        <group group_id="B4">
          <title>Brivaracetam 100 mg/Day</title>
          <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
        </group>
        <group group_id="B5">
          <title>Total Title</title>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="100"/>
            <count group_id="B2" value="99"/>
            <count group_id="B3" value="100"/>
            <count group_id="B4" value="100"/>
            <count group_id="B5" value="399"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36.4" spread="13.0"/>
                    <measurement group_id="B2" value="35.7" spread="12.5"/>
                    <measurement group_id="B3" value="39.0" spread="13.5"/>
                    <measurement group_id="B4" value="38.0" spread="13.1"/>
                    <measurement group_id="B5" value="37.24" spread="13.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="96"/>
                    <measurement group_id="B2" value="94"/>
                    <measurement group_id="B3" value="97"/>
                    <measurement group_id="B4" value="96"/>
                    <measurement group_id="B5" value="383"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="45"/>
                    <measurement group_id="B4" value="42"/>
                    <measurement group_id="B5" value="171"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="61"/>
                    <measurement group_id="B3" value="55"/>
                    <measurement group_id="B4" value="58"/>
                    <measurement group_id="B5" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>India</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="23"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Belgium</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Finland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>France</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Netherlands</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Switzerland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period</title>
        <description>Partial (Type I) Seizures can be classified into one of the following three groups: Simple Partial Seizures, Complex Partial Seizures, Partial Seizures evolving to Secondarily Generalized Seizures.</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Partial Onset Seizure (Type I) Frequency Per Week Over the 12-week Treatment Period</title>
          <description>Partial (Type I) Seizures can be classified into one of the following three groups: Simple Partial Seizures, Complex Partial Seizures, Partial Seizures evolving to Secondarily Generalized Seizures.</description>
          <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.</population>
          <units>Seizure Frequency per Week</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" lower_limit="0.76" upper_limit="5.12"/>
                    <measurement group_id="O2" value="1.34" lower_limit="0.70" upper_limit="3.12"/>
                    <measurement group_id="O3" value="1.49" lower_limit="0.69" upper_limit="2.78"/>
                    <measurement group_id="O4" value="1.26" lower_limit="0.52" upper_limit="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>In order to control the Type I error testing was performed in sequence starting with 50 mg, then 100 mg and finally 20 mg Brivaracetam per day versus Placebo, only moving to the next test if the previous one was significant at the 5 % level.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>=0.261</p_value>
            <method>ANCOVA</method>
            <param_type>Percentage Reduction over Placebo</param_type>
            <param_value>6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.2</ci_lower_limit>
            <ci_upper_limit>16.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Responder Rate for Partial Onset Seizures (Type I) Frequency Per Week Over the 12-week Treatment Period</title>
        <description>Responders are those subjects with at least 50 % reduction from Baseline to Treatment Period in Partial Onset Seizure frequency per week.
The Responder Rate for Partial Onset Seizures (Type I) is the proportion of subjects who have a &gt;= 50 % reduction in seizure frequency per week from Baseline.</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Responder Rate for Partial Onset Seizures (Type I) Frequency Per Week Over the 12-week Treatment Period</title>
          <description>Responders are those subjects with at least 50 % reduction from Baseline to Treatment Period in Partial Onset Seizure frequency per week.
The Responder Rate for Partial Onset Seizures (Type I) is the proportion of subjects who have a &gt;= 50 % reduction in seizure frequency per week from Baseline.</description>
          <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.0"/>
                    <measurement group_id="O2" value="72.7"/>
                    <measurement group_id="O3" value="72.7"/>
                    <measurement group_id="O4" value="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="27.3"/>
                    <measurement group_id="O3" value="27.3"/>
                    <measurement group_id="O4" value="36.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>All Seizure Frequency (Type I+II+III) Per Week Over the 12-week Treatment Period</title>
        <description>There are three types of Epilepsy: Partial Epilepsies (Type I), Generalized Epilepsies (Type II) and uncertain classification of Epilepsies (Type III).</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>All Seizure Frequency (Type I+II+III) Per Week Over the 12-week Treatment Period</title>
          <description>There are three types of Epilepsy: Partial Epilepsies (Type I), Generalized Epilepsies (Type II) and uncertain classification of Epilepsies (Type III).</description>
          <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.</population>
          <units>Times per week</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" lower_limit="0.76" upper_limit="5.61"/>
                    <measurement group_id="O2" value="1.34" lower_limit="0.70" upper_limit="3.12"/>
                    <measurement group_id="O3" value="1.49" lower_limit="0.69" upper_limit="2.78"/>
                    <measurement group_id="O4" value="1.26" lower_limit="0.52" upper_limit="2.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent Change From Baseline to the 12-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week</title>
        <description>The percent change from Baseline was computed as: Weekly Seizure Frequency (Treatment) - Weekly Seizure Frequency (Baseline) / Weekly Seizure Frequency (Baseline) * 100. Negative values indicate a reduction from Baseline with higher negative values showing higher reduction.</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change From Baseline to the 12-week Treatment Period in Partial Onset Seizure (Type I) Frequency Per Week</title>
          <description>The percent change from Baseline was computed as: Weekly Seizure Frequency (Treatment) - Weekly Seizure Frequency (Baseline) / Weekly Seizure Frequency (Baseline) * 100. Negative values indicate a reduction from Baseline with higher negative values showing higher reduction.</description>
          <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.</population>
          <units>Percent change in seizures per week</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.03" lower_limit="-40.27" upper_limit="17.59"/>
                    <measurement group_id="O2" value="-30.03" lower_limit="-55.99" upper_limit="-2.11"/>
                    <measurement group_id="O3" value="-26.83" lower_limit="-60.05" upper_limit="6.32"/>
                    <measurement group_id="O4" value="-32.45" lower_limit="-72.51" upper_limit="0.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Categorized Percentage Change From Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the 12-week Treatment Period</title>
        <description>The categories are:
&lt;= 25 %
- 25 % to &lt; 25 %
25 % to &lt; 50 %
50 % to &lt; 75 %
75 % to &lt; 100 %
100 %</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Categorized Percentage Change From Baseline in Seizure Frequency for Partial Onset Seizure (Type I) Over the 12-week Treatment Period</title>
          <description>The categories are:
&lt;= 25 %
- 25 % to &lt; 25 %
25 % to &lt; 50 %
50 % to &lt; 75 %
75 % to &lt; 100 %
100 %</description>
          <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>&lt;= 25 %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0"/>
                    <measurement group_id="O2" value="10.1"/>
                    <measurement group_id="O3" value="15.2"/>
                    <measurement group_id="O4" value="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>- 25 % to &lt; 25 %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0"/>
                    <measurement group_id="O2" value="35.4"/>
                    <measurement group_id="O3" value="33.3"/>
                    <measurement group_id="O4" value="33.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>25 % to &lt; 50 %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0"/>
                    <measurement group_id="O2" value="27.3"/>
                    <measurement group_id="O3" value="24.2"/>
                    <measurement group_id="O4" value="21.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50 % to &lt; 75 %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0"/>
                    <measurement group_id="O2" value="18.2"/>
                    <measurement group_id="O3" value="17.2"/>
                    <measurement group_id="O4" value="14.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75 % to &lt; 100 %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.0"/>
                    <measurement group_id="O2" value="7.1"/>
                    <measurement group_id="O3" value="9.1"/>
                    <measurement group_id="O4" value="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>100 %</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="1.0"/>
                    <measurement group_id="O4" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Seizure Freedom Rate (All Seizure Types) Over the 12-week Treatment Period</title>
        <description>Subjects were considered seizure free if their seizure counts for every day over the entire Treatment Period was zero and if they completed the Treatment Period.</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Seizure Freedom Rate (All Seizure Types) Over the 12-week Treatment Period</title>
          <description>Subjects were considered seizure free if their seizure counts for every day over the entire Treatment Period was zero and if they completed the Treatment Period.</description>
          <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Seizure free</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2.0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Seizures but non-completer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1.0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Seizure-free</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0"/>
                    <measurement group_id="O2" value="98.0"/>
                    <measurement group_id="O3" value="99.0"/>
                    <measurement group_id="O4" value="96.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Type I Seizure During the 12-week Treatment Period</title>
        <description>The time to first Type I Seizure during the 12-week Treatment Period was measured in days.</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Type I Seizure During the 12-week Treatment Period</title>
          <description>The time to first Type I Seizure during the 12-week Treatment Period was measured in days.</description>
          <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" lower_limit="3" upper_limit="5"/>
                    <measurement group_id="O2" value="6" lower_limit="3" upper_limit="8"/>
                    <measurement group_id="O3" value="6" lower_limit="4" upper_limit="10"/>
                    <measurement group_id="O4" value="4" lower_limit="3" upper_limit="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Fifth Type I Seizure During the 12-week Treatment Period</title>
        <description>The time to Fifth Type I Seizure during the 12-week Treatment Period was measured in days.</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Fifth Type I Seizure During the 12-week Treatment Period</title>
          <description>The time to Fifth Type I Seizure during the 12-week Treatment Period was measured in days.</description>
          <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19" lower_limit="14" upper_limit="25"/>
                    <measurement group_id="O2" value="25" lower_limit="20" upper_limit="34"/>
                    <measurement group_id="O3" value="24" lower_limit="20" upper_limit="32"/>
                    <measurement group_id="O4" value="24" lower_limit="18" upper_limit="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Tenth Type I Seizure During the 12-week Treatment Period</title>
        <description>The time to tenth Type I Seizure during the 12-week Treatment Period was measured in days.</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Tenth Type I Seizure During the 12-week Treatment Period</title>
          <description>The time to tenth Type I Seizure during the 12-week Treatment Period was measured in days.</description>
          <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="100"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="99"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39" lower_limit="24" upper_limit="50"/>
                    <measurement group_id="O2" value="49" lower_limit="36" upper_limit="64"/>
                    <measurement group_id="O3" value="40" lower_limit="33" upper_limit="49"/>
                    <measurement group_id="O4" value="46" lower_limit="34" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Reduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 12- Week Treatment Period.</title>
        <description>The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period.</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.
Type IC Population consists of those subjects with at least one Type IC seizure during the Baseline period.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction of Type IC/Type I Seizure Frequency Ratio From Baseline to the 12- Week Treatment Period.</title>
          <description>The type IC/Type I seizure frequency ratio is represented by the percentage of subjects having a reduction in the ratio of Type IC seizure frequency over Type IA, IB, and IC seizure frequency from Baseline to Treatment Period.</description>
          <population>The Intention-to-treat (ITT) population was defined as all randomized subjects who received at least 1 dose of study medication.
Type IC Population consists of those subjects with at least one Type IC seizure during the Baseline period.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="37"/>
                <count group_id="O2" value="36"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.9"/>
                    <measurement group_id="O2" value="47.2"/>
                    <measurement group_id="O3" value="62.5"/>
                    <measurement group_id="O4" value="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</title>
        <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>Subjects in the Intention-To-Treat (ITT) population with measurements at Baseline and Last Visit / Early Discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the 12-week Treatment Period in Total Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</title>
          <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
          <population>Subjects in the Intention-To-Treat (ITT) population with measurements at Baseline and Last Visit / Early Discontinuation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="94"/>
                <count group_id="O4" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.29" spread="14.03"/>
                    <measurement group_id="O2" value="4.50" spread="12.71"/>
                    <measurement group_id="O3" value="3.09" spread="14.43"/>
                    <measurement group_id="O4" value="1.78" spread="13.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</title>
        <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>Subjects in the Intention-To-Treat (ITT) population with measurements at Baseline and Last Visit / Early Discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the 12-week Treatment Period in Seizure Worry Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</title>
          <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
          <population>Subjects in the Intention-To-Treat (ITT) population with measurements at Baseline and Last Visit / Early Discontinuation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.25" spread="22.01"/>
                    <measurement group_id="O2" value="6.23" spread="17.97"/>
                    <measurement group_id="O3" value="5.34" spread="23.81"/>
                    <measurement group_id="O4" value="8.04" spread="26.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the 12-week Treatment Period in Daily Activities/Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</title>
        <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit / Early Discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the 12-week Treatment Period in Daily Activities/Social Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</title>
          <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
          <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit / Early Discontinuation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.09" spread="20.26"/>
                    <measurement group_id="O2" value="3.35" spread="19.72"/>
                    <measurement group_id="O3" value="3.09" spread="20.79"/>
                    <measurement group_id="O4" value="3.50" spread="22.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the 12-week Treatment Period in Hospital Anxiety Score</title>
        <description>The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period.</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit / Early Discontinuation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the 12-week Treatment Period in Hospital Anxiety Score</title>
          <description>The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period.</description>
          <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit / Early Discontinuation.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.54" spread="3.89"/>
                    <measurement group_id="O2" value="-0.59" spread="3.89"/>
                    <measurement group_id="O3" value="-0.41" spread="3.82"/>
                    <measurement group_id="O4" value="0.08" spread="3.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the 12-week Treatment Period in Hospital Depression Score</title>
        <description>The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period.</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit / Early Discontinuation Visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the 12-week Treatment Period in Hospital Depression Score</title>
          <description>The Hospital Anxiety and Depression Scale (HADS) was used to evaluate anxiety and depression simultaneously. The HADS was developed as a self-administered scale that has been designed to assess the presence and severity of both anxiety and depression. It consists of 14 items that are scored on a 4-point severity scale ranging from 0 to 3. A score per dimension was calculated with each score ranging from 0 to 21 and higher scores indicating higher depression / anxiety. Negative values in Change from Baseline indicate a decrease of HADS from Baseline to Treatment Period.</description>
          <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit / Early Discontinuation Visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="91"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.65" spread="3.58"/>
                    <measurement group_id="O2" value="-0.10" spread="3.67"/>
                    <measurement group_id="O3" value="0.26" spread="3.84"/>
                    <measurement group_id="O4" value="-0.24" spread="3.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit</title>
        <description>The Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The subject not mentally impaired had to complete it by answering the following question: “Overall, has there been a change in your seizures since the start of the study medication?”</description>
        <time_frame>Last Visit or Early Discontinuation Visit in the 12-week Treatment Period</time_frame>
        <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit or Early Discontinuation Visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Patient's Global Evaluation Scale (P-GES) Evaluated at Last Visit or Early Discontinuation Visit</title>
          <description>The Patient's Global Evaluation Scale (P-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement) with the start of the study medication as the reference time point. The subject not mentally impaired had to complete it by answering the following question: “Overall, has there been a change in your seizures since the start of the study medication?”</description>
          <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit or Early Discontinuation Visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="90"/>
                <count group_id="O3" value="90"/>
                <count group_id="O4" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.93" spread="1.39"/>
                    <measurement group_id="O2" value="5.17" spread="1.27"/>
                    <measurement group_id="O3" value="5.04" spread="1.29"/>
                    <measurement group_id="O4" value="5.47" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit</title>
        <description>The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement), with the start of the study medication as reference time point. The Investigator was to complete it by answering the following question: “Assess the Overall change in the severity of patient’s illness, compared to start of study medication.”</description>
        <time_frame>Last Visit or Early Discontinuation Visit in the 12-week Treatment Period</time_frame>
        <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit or Early Discontinuation Visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator's Global Evaluation Scale (I-GES) Evaluated at Last Visit or Early Discontinuation Visit</title>
          <description>The Investigator's Global Evaluation Scale (I-GES) is a global assessment of the disease evolution which was performed using a seven-point scale (1 = Marked worsening to 7 = Marked improvement), with the start of the study medication as reference time point. The Investigator was to complete it by answering the following question: “Assess the Overall change in the severity of patient’s illness, compared to start of study medication.”</description>
          <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit or Early Discontinuation Visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="96"/>
                <count group_id="O2" value="99"/>
                <count group_id="O3" value="98"/>
                <count group_id="O4" value="100"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.78" spread="1.20"/>
                    <measurement group_id="O2" value="4.99" spread="1.15"/>
                    <measurement group_id="O3" value="4.99" spread="1.10"/>
                    <measurement group_id="O4" value="5.34" spread="1.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the 12-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</title>
        <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit or Early Discontinuation Visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the 12-week Treatment Period in Energy/Fatigue Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</title>
          <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
          <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit or Early Discontinuation Visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="86"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="83"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.49" spread="19.22"/>
                    <measurement group_id="O2" value="3.53" spread="17.04"/>
                    <measurement group_id="O3" value="1.95" spread="20.74"/>
                    <measurement group_id="O4" value="1.99" spread="20.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the 12-week Treatment Period in Emotional Well-Being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</title>
        <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit or Early Discontinuation Visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the 12-week Treatment Period in Emotional Well-Being Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</title>
          <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
          <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit or Early Discontinuation Visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.80" spread="18.71"/>
                    <measurement group_id="O2" value="3.75" spread="15.94"/>
                    <measurement group_id="O3" value="3.13" spread="19.35"/>
                    <measurement group_id="O4" value="-2.45" spread="18.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the 12-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</title>
        <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit or Early Discontinuation Visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the 12-week Treatment Period in Cognitive Functioning Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</title>
          <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
          <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit or Early Discontinuation Visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="85"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.80" spread="19.16"/>
                    <measurement group_id="O2" value="5.36" spread="20.69"/>
                    <measurement group_id="O3" value="1.02" spread="19.95"/>
                    <measurement group_id="O4" value="0.69" spread="16.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the 12-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</title>
        <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit or Early Discontinuation Visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the 12-week Treatment Period in Medication Effects Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</title>
          <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
          <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit or Early Discontinuation Visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="92"/>
                <count group_id="O3" value="96"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.92" spread="28.93"/>
                    <measurement group_id="O2" value="3.64" spread="29.24"/>
                    <measurement group_id="O3" value="-0.85" spread="24.36"/>
                    <measurement group_id="O4" value="3.00" spread="28.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the 12-week Treatment Period in Overall Quality of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</title>
        <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit or Early Discontinuation Visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the 12-week Treatment Period in Overall Quality of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</title>
          <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
          <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit or Early Discontinuation Visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="86"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.11" spread="18.48"/>
                    <measurement group_id="O2" value="4.52" spread="16.73"/>
                    <measurement group_id="O3" value="4.55" spread="18.93"/>
                    <measurement group_id="O4" value="2.24" spread="18.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to the 12-week Treatment Period in Health Status of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</title>
        <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
        <time_frame>From Baseline to 12-week Treatment Period</time_frame>
        <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit or Early Discontinuation Visit.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Matching Placebo tablets administered twice a day</description>
          </group>
          <group group_id="O2">
            <title>Brivaracetam 20 mg/Day</title>
            <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
          </group>
          <group group_id="O3">
            <title>Brivaracetam 50 mg/Day</title>
            <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
          </group>
          <group group_id="O4">
            <title>Brivaracetam 100 mg/Day</title>
            <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to the 12-week Treatment Period in Health Status of Life Patient Weighted Quality of Life in Epilepsy Inventory-Form 31 (QOLIE-31-P) Score</title>
          <description>The QOLIE-31-P is an adaptation of the original QOLIE-31 instrument that includes 30 items grouped into seven multi-item subscales - Seizure Worry (5 items), Overall Quality of Life (2 items), Emotional Well-Being (5 items), Energy/Fatigue (4 items), Cognitive Functioning (6 items), Medication Effects (3 items) and Daily Activities/Social Functioning (5 items) - and a Health Status item. The subscale scores, the Total score and the Health Status item score are calculated according to the scoring algorithm defined by the author with scores ranging from 0 to 100 and higher scores indicating better function. A positive value in Change from Baseline indicates an improvement from Baseline.</description>
          <population>Subjects in the Intention-to-treat (ITT) population with measurements at Baseline and Last Visit or Early Discontinuation Visit.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="93"/>
                <count group_id="O3" value="95"/>
                <count group_id="O4" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="16.3"/>
                    <measurement group_id="O2" value="6.9" spread="20.1"/>
                    <measurement group_id="O3" value="9.7" spread="19.8"/>
                    <measurement group_id="O4" value="4.9" spread="18.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AEs) were collected up to 23 weeks from Visit 1 (Week -8) to the Safety Visit (Week 15).</time_frame>
      <desc>Adverse Events (AEs) refer to the Safety Set (SS) population wich contains the same set of subjects as the Intention-To-Treat (ITT) population.</desc>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>Matching Placebo tablets administered twice a day</description>
        </group>
        <group group_id="E2">
          <title>Brivaracetam 20 mg/Day</title>
          <description>Brivaracetam 20 mg/day, 10 mg administered twice a day</description>
        </group>
        <group group_id="E3">
          <title>Brivaracetam 50 mg/Day</title>
          <description>Brivaracetam 50 mg/day, 25 mg administered twice a day</description>
        </group>
        <group group_id="E4">
          <title>Brivaracetam 100 mg/Day</title>
          <description>Brivaracetam 100 mg/day, 50 mg administered twice a day</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Jaw fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Grand mal convulsion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Psychotic Disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="100"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="99"/>
                <counts group_id="E3" subjects_affected="35" subjects_at_risk="99"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="100"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="99"/>
                <counts group_id="E4" events="26" subjects_affected="8" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="7" subjects_affected="6" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="100"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="99"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="99"/>
                <counts group_id="E4" events="9" subjects_affected="8" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="100"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="99"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="11" subjects_affected="5" subjects_at_risk="100"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E3" events="12" subjects_affected="7" subjects_at_risk="99"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="14" subjects_affected="10" subjects_at_risk="100"/>
                <counts group_id="E2" events="19" subjects_affected="14" subjects_at_risk="99"/>
                <counts group_id="E3" events="31" subjects_affected="18" subjects_at_risk="99"/>
                <counts group_id="E4" events="15" subjects_affected="9" subjects_at_risk="100"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="100"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="99"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="99"/>
                <counts group_id="E4" events="8" subjects_affected="8" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="100"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="99"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="99"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="100"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCB Clinical Trial Call Center</name_or_title>
      <organization>UCB</organization>
      <phone>+1 877 822 9493</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

